Search

Your search keyword '"Dragnic S"' showing total 1 results
Start Over Author "Dragnic S" Topic androgen deprivation therapy
1 results on '"Dragnic S"'

1. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies

Author

Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, Gruca D, and Norton M

Subjects
androgen deprivation therapy, gonadotropin-releasing hormone analog, prostate cancer, castrate levels, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Aaron Spitz,1 Marc Gittelman,2 Lawrence I Karsh,3 Sanja Dragnic,4 Ahmed M Soliman,5 Aditya Lele,6 Damian Gruca,7 Michael Norton4 1Orange County Urology Associates, Laguna Beach, CA, 221st Century Oncology/UroMedix-Aventura Division, Aventura, FL, 3The Urology Center of Colorado, Denver, CO, 4US Medical Affairs, 5Health Economics and Outcomes Research, 6Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA; 7Global Medical Affairs, AbbVie Deutschland, Ludwigshafen, Germany Introduction: Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) analogs is a standard treatment for advanced prostate cancer. GnRH analog therapy can reduce testosterone to “castrate” levels, historically defined as

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results